ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Eric Van Cutsem et al.|Annals of Oncology|2012Cited by 1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal CancerScott Kopetz, Josep Tabernero, Per Pfeiffer et al.|New England Journal of Medicine|2019Cited by 1.5k
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Takashi Kojima et al.|JAMA Oncology|2018Cited by 518
Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upThierry Conroy, Michel Ducreux, Per Pfeiffer et al.|Annals of Oncology|2023Cited by 502
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S. Fuchs, Francesco Di Costanzo, Kohei Shitara et al.|The Lancet Oncology|2019Cited by 282